

BIBLIOGRAPHIE : Psilocybes - Psilocybine

Ethnologie, Psychiatrie, Pharmacologie, Toxicologie,

Neurophysiologie, Expériences mystiques, Usages

thérapeutiques...

Docteur Christian SUEUR, GRECC, décembre 2019

1- Psilocybine / psilocybes : généralités

1. BANCOPUMA : Psilocybin : The Science behind a Magical Molecule, The Nexian, 20 november 2014.
www.The-nexian.me/home/knowledge/142-psilocybin-the-science-behind-a-magical-molecule
2. COX D.J., GRIFFITHS R.R. : Psilocybin and Social Behavior, 2019, pdf.
3. DAVIS K. : What are magic mushrooms and psilocybin ?, *Medical News Today*, 2019.
www.medicalnewstoday.com/articles/308850.php
4. DIAZ J.L. : Ethnopharmacology and Taxonomy of Mexican Psychodysleptic Plants, *Journal of Psychedelic Drugs*, 1979, 11, (1-2), 71-101.
PMID : 392121
5. DOLAN S.B., GARCIA-ROMEU A., GRIFFITHS R.R., JOHNSON M.W. : Using Behavioral Economics to Assess the Enduring Effects of Psilocybin, *Psychedelics as Behavior Change Agents*, Conference : American Psychology Association Annual Convention, at Chicago, IL, 2019, ppt.
https://www.researchgate.net/publication/335474550_Using_Behavioral_Economics_to_Assess_the_Enduring_Effects_of_Psilocybin
6. EMCDDA : Champignons hallucinogènes.
<http://www.emcdda.europa.eu/publications/drug-profiles/mushrooms>
7. FABRE A. : La Psilocybine : de son utilisation ancienne au cours de rituels chamaniques à sa consommation récréative actuelle en passant par son intérêt pharmaceutique, *Thèse pour le Diplôme d'Etat de Docteur en Pharmacie, 16 décembre 2013, Université Claude Bernard – Lyon 1, Faculté de Pharmacie*.
8. FADIMAN J. : The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys, *Inner Traditions Bear and Company*, 2011.
9. FREDERIC L. : Usages ancestraux et actuels des champignons sacrés Teonanacatl, Mémoire de Diplôme d'Etat de Docteur en Pharmacie, Université Louis Pasteur de Strasbourg, 17/06/1997.
10. GUZMAN G. : The Genus Psilocybe : A Systematic Revision of the Known Species Including the History, Distribution and Chemistry of the Hallucinogenic Species, *Beihefte zur Nova Hedwigia Heft 74*, J. Cramer, Vaduz, Germany, 1983.
11. HAACKE A. : Psilocybin : A Blueprint to a Better World, *Taileaters*, 2019.
www.taileaters.com/psychedelics/psilocybin/psilocybin/
12. HASLER F., GRIMBERG U., BENZ M.A., HUBER T., VOLLENWEIDER F.X. : Acute

- psychological and physiological effects of psilocybin in healthy humans : a double-bind, placebo-controlled dose-effect study, *Psychopharmacology*, 2004, 172, 145-156.
Doi : 10.1007/s00213-003-1640-6
13. HATSIS T. : Microdosing magic : A psychedelic spellbook, Psanctum Psychedelia Press, Portland, Oregon, 2018.
14. JOHNSON M.W., HENDRICKS P.S., BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : An integrative review of epidemiology, therapeutics, mystical experience, and brain network function, *Pharmacology & Therapeutics*, 2018, Doi : 10.1016/j.pharmthera.2018.11.010
15. NAVET E. : Les voies de l'Amanite Tue-mouche (*Amanita Muscaria*), in Baud S. et Ghasarian C. « *Des plantes psychotropes. Initiations, thérapies et quêtes de soi* », Editions Imago, Paris, 2010, 61-78.
16. STUDERUS E., GAMMA A., KOMETER M., VOLLENWEIDER F.X. : Prediction of Psilocybin Response in Healthy Volunteers, *PLOS One*, 2012, 7, 2, e30800.
17. THORICATHA W., It is Time to Legalize Psilocybin Mushrooms, *Psychedelic Times*, 2019, June 6.
www.psychedelictimes.com/it-is-time-to-legalize-psilocybin-mushrooms
18. TYLS F., PALENICEK T., HORACEK J. : Psilocybin – Summary of knowledge and new perspectives, *European Neuropsychopharmacology*, 2014, 24, 342-356.
Doi : 10.1016/j.euroneuro.2013.12.006
19. WENIGER B. : Les champignons psychotropes d'Amérique Centrale, in Baud S. et Ghasarian C. « *Des plantes psychotropes. Initiations, thérapies et quêtes de soi* », Editions Imago, Paris, 2010, 79-88.

2- Psilocybes : ethnologie

1. ALLEN J.W., MERLIN M.D., JANSEN K.L.R. : An Ethnomycological Review of Psychoactive Agarics in Australia and New Zealand, *Journal of Psychoactive Drugs*, 1991, 23, (1), 39-69.
2. CHAVOT P. : Le champignon des dieux. L'amanite tue-mouche, 2005.
3. DIAZ J.L. : Ethnopharmacology and Taxonomy of Mexican Psychodysleptic Plants, *Journal of Psychedelic Drugs*, 1979, 11, (1-2), 71-101.
PMID : 392121
4. EXBALIN A. : Discovering hallucinogenic mushrooms in Mexico, *The Conversation*, 12 avril 2019, 6 p.
<https://theconversation.com/discovering-hallucinogenic-mushrooms-in-mexico-115033>
5. GUZMAN, ALLEN, GARTZ : A Worldwide Geographical Distribution of the Neurotropic Fungi, an Analysis and Discussion, 1992.
6. HOFMANN A., RATSCH C., SCHULTES R. : Plants of the Gods : Their Sacred, Healing, and Hallucinogenic Powers, Rochester, Healing Arts Press, 1992.
7. SMITH H. : Cleansing the Doors of Perception : The Religious Significance of Entheogenic Plants and Chemicals, Tarcher/Putnam, 2000.
ISBN 1-58542-034-4

8. LEVI-STRAUSS C. : Les champignons dans la culture. A propos d'un livre de M. R.G. Wasson (1970), *Anthropologie Structurale II*, 1973.
https://www.persee.fr/doc/hom_0439-4216_1970_num_10_1_367101
9. PHARAND M. : The Mythophile and the Mycophile : Robert Graves and R. Gordon Wasson.
10. SAMORINI G. : Traditional use of psychoactive mushrooms in Ivory Coast ?, *Eleusis – Journal of Psychoactive Plants and Compound*, 1995, 1, 22-27.
<http://users.lycaeum.org/>
11. SAMORINI G. : New Data from the Ethnomycology of Psychoactive Mushrooms, *International Journal of Medicinal Mushrooms*, 2001, Vol. 3, 257-278.
<https://www.samorini.it/doc1/sam/samorini-new-data-from-ethnomycology.pdf>
12. WASSON R. : Seeking the magic mushroom, *LIFE*, 1957, 100-120.
13. WASSON R. : I ate the sacred mushrooms, *This Week*, 1957, 19 May, 8-10, 36.
14. WASSON R.G. : The Hallucinogenic Fungi Of Mexico. An inquiry Into The Origins of The Religious Idea Among Primitive Peoples, *Botanical Museum Leaflets*, Harvard University, 1961, 19, 7.
Reprinted in *The Psychedelic Review*, 1963, 1, 27-42.
<http://druglibrary.net/schaffer/lsd/wasson.htm>
15. WASSON R.G. : Soma. Divine Mushroom of Immortality, Harcourt Brace Jovanovich Inc., Italy, 380 p.

"Mushroom and Religion: Conocybe, Panaeolus, Psilocybe and Stropharia."
Botany.hawaii.edu, n.d.

<http://www.botany.hawaii.edu/faculty/wong/BOT135/Lect20b.htm>

3- Psilocybine : clinique psychiatrique

1. BARNBY J.M., MEHTA M.A. : Psilocybin and Mental Health – Don't Lose Control, *Frontiers in Psychiatry*, 2018, 9, article 293.
Doi : 10.3389/fpsyg.2018.00293
2. DIGONNET C., DEFAYOLLE J.M., STEYAERT M. : Des champignons hallucinogènes en France : c'est la bouse qui deale !, *Perspectives Psychiatriques*, 1987, 26, 10/V, 348-351.
3. ESPIARD M.-L., LECARDEUR L., ABADIE P., HALBECQ I., DOLLFUS S. : Hallucinogen persisting perception disorder after psilocybin consumption : a case study, *European Psychiatry*, 2005, 23-41.
Doi : 10.1016/j.eurpsy.2005.04.008
4. FLORES J.R. : Psicosindrome experimental con psilocibina, Clinica de Psiquiatria de la Universidad Peruana « Cayetano Heredia », Lima.
5. HOFMANN A. : Rapport sur une auto-experience avec le *Psilocybe mexicana* Heim, in Heim R., Wasson R.G. : Les champignons hallucinogènes du Mexique, Ed Museum National d'Histoire Naturelle, Paris, 1958, pp 278-280.
6. MALITZ S., ESECOVER H., WILKENS B., HOCH P.H. : Some Observations on Psilocybin, a New Hallucinogen, in Volunteer Subjects, *Comprehensive Psychiatry*, 1960, 1, (1), 8-17.
7. POKORNY T., PRELLER K.H., KOMETER M., DZIOBEK I., VOLLENWEIDER F.X. : effect of Psilocybin on Empathy and Moral Decision-Making, *The International Journal of Neuropsychopharmacology*, 2017, 20, (9), 747-757.
Doi : 10.1093/ijnp/pyx047
8. RINKEL M., ATWELL C., DIMASCIO A., BROWN J. : Experimental Psychiatry V. Psilocybine, a new psychotogenic drug, *New England Journal of Medicine*, 1960, 262, 295-297.
9. RINKEL M., DIMASCIO A., ROBEY A., ATWELL C. : Personnalité patterns and reaction to psilocybine, 273-279.
10. SPITZER M., THIMM M., HERMLE L., HOLZMANN P., KOVAR K.-A., HEIMANN H., GOUZOULIS-MAYFRANK E., KISCHKA U., SCHNEIDER F. : Increased Activation of Indirect Semantic Associations under Psilocybin, *Biological Psychiatry*, 1996, 39, 1055-1057.
11. SUPPRIAN T., SUPPRIAN R., ROSLER M., WANKE K. : Psychoactive mushrooms – an update, *Fortschritte der Neurologie Psychiatrie*, 2001, 69, (12), 597-602.

4- Psilocybine : pharmacologie

1. BECK J., GORDEN D. : Psilocybian Mushrooms, *PharmChem Newsletter*, vol. 11, n°1.
2. BROWN R.T., NICHOLAS C.R., COZZI N.V., GASSMAN M.C., COOPER K.M., MULLER D. et al. : Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults, *Clinical Pharmacokinetics*, 2017, 56, (12), 1543-54.
3. CHRISTIANSEN A.L., RASMUSSEN K.E. : Screening of hallucinogenic mushrooms with high-performance liquid chromatography and multiple detection, *Journal of Chromatography*, 1983, 270, 293-299.
4. CIPRIANI A., FURUKAWA T.A., SALANTI G., CHAIMANI A., ATKINSON L.Z., OGAWA Y., Leucht, S., RUHE H.G., TURNER E.H., HIGGINS J.P.T., EGGER M., TAKESHIMA N., HAYASAKA Y., IMAI H., SHINOHARA K., TAJIKA A., IOANNIDIS J.P.A., GEDDES J.R. : Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, *Lancet*, 2018, 391, 1357– 1366.
5. DINIS-OLIVEIRA R.J. : Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance, *Drug Metabolism Reviews*, 2017, 49, (1), 84-91.
6. GARTZ J. : New aspects of the occurrence, chemistry and cultivation of european hallucinogenic mushrooms, *Annali dei Musei Civici di Rovereto Sezione Archeologica, Storia e Scienze Naturali*, 1992, vol. 8.
<http://www.lycaeum.org/drugs/Tryptamines/Psilocybian/gartz3.html>
7. GUZMAN G. : The Genus Psilocybe : A Systematic Revision of the Known Species Including the History, Distribution and Chemistry of the Hallucinogenic Species, Beihefte zur Nova Hedwigia Heft 74, J. Cramer, Vaduz, Germany, 1983.
8. HASLER F., BOURQUIN D., BRENNISEN R., BÄR T., VOLLENWEIDER F.X. : Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man, *Pharmaceutica Acta Helvetiae*, 1997, 72, (3), 175-84.
9. HASLER F., GRIMBERG U., BENZ M.A., HUBERT., VOLLENWEIDER F.X. : Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study, *Psychopharmacology (Berl)*, 2004, 172, (2), 145-56
10. HEIM R., WASSON R.G. : Les champignons hallucinogènes du Mexique, Etudes ethnologiques, taxinomiques, biologiques, physiologiques et chimiques, *Archives du Museum*, séries7, t.VI, 1958, Ed. Museum National d'Histoire Naturelle, Paris.
11. HEIM R., HOFMANN A. : La psilocybine et la psilocine chez les psilocybes et strophaires hallucinogènes, in HEIM R. & WASSON R.G. : « *Les champignons hallucinogènes du Mexique* », Ed Museum National d'Histoire Naturelle, Paris, 1958, 258-262.
12. HEIM R., HOFMANN A. : Isolement de la psilocybine à partir du Stropharia cubensis Earle et d'autres espèces de champignons hallucinogènes mexicains appartenant au genre Psilocybe, Extrait des Compte rendus des séances de l'Académie des Sciences, (séance du 4 août 1958), *Revue de Mycologie*, 1958, 22, 24-28.
13. HEIM R. : Les Champignons Toxiques et Hallucinogènes, Editions N. Boubée & Cie, Paris, 1963.

14. HEIM R. : Histoire de la Découverte des Champignons Hallucinogènes du Mexique, in « *Mandala – Essai sur l'expérience hallucinogène* », Editions Pierre Belfond, 1969, pp 173-195.
15. HEIM R., HOFMANN A. : La Folie des Kuma, in « *Mandala – Essai sur l'expérience hallucinogène* », Editions Pierre Belfond, 1969, pp 196-211.
16. HOLLISTER L.E. : Clinical, Biochemical and Psychologic Effects of Psilocybin *Archives Internationales de Pharmacodynamie et de Thérapie*, 1961, 130, 42-52.
17. HOFMANN A., FREY A., OTT H., PETRZILSKAT., TROXLER F. : Détermination de la structure et synthèse de la psilocybine, in HEIM R. & WASSON R.G. : « *Les champignons hallucinogènes du Mexique* », Ed Museum National d'Histoire Naturelle, Paris, 1958, 263-267.
18. HOFMANN A., HEIM R., BRACK A., KOBEL H. : La psilocybine, principe actif psychotrope extrait du champignon hallucinogène, in HEIM R. & WASSON R.G. : « *Les champignons hallucinogènes du Mexique* », Ed Museum National d'Histoire Naturelle, Paris, 1958, 255-257.
19. HOFMANN A. : Rapport sur une auto-experience avec le *Psilocybe Mexicana* Heim, in HEIM R. & WASSON R.G. : « *Les champignons hallucinogènes du Mexique* », Ed Museum National d'Histoire Naturelle, Paris, 1958, 278-280.
20. HOFMANN A. : Chemical aspects of psilocybin, the psychotropic principle from the Mexican Fungus *Psilocybe Mexicana Heim*, *Proceedings of the 1st International Congress of Neuro-Psychopharmacology*, Rome September 1958, Ed. by P.B. Bradley, P. Denoker, C. Radouco-Thomas, Elsevier Amsterdam, London , New York, Princeton, 1959, 446-448.
21. JEROME L. : Psilocybine, Investigator's Brochure, March-April 2007.
22. KOSENTKA P., SPRAGUE S.L., RYBERG M., GARTZ J., MAY A.L., CAMPAGNA S.R., et al. : Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi, *PLoS One*, 2013, 8, 5, e64646.
23. MUSSHOF F., MADEA B., BEIKE J. : Hallucinogenic mushrooms on the German market – simple instructions for examination and identification, *Forensic Science International*, 2000, 113, (1-3), 389-395.
24. NICHOLAS C.R., HENRIQUEZ K.M., GASSMAN M.C., COOPER K.M., MULLER D., HETZEL S., BROWN R.T., COZZI N.V., THOMAS C., HUTSON P.R. : High dose psilocybin is associated with positive subjective effects in healthy volunteers, *Journal of Psychopharmacology*, 2018.
Doi : 10.1177/0269881118780713
25. PASSIE T., SEIFERT J., SCHNEIDER U., EMRICH H.M. : The pharmacology of psilocybin, *Addiction Biology*, 2002, 7, (4), 357-364.
26. PEDERSEN-BJERGAARD S., SANNE E., RASMUSSEN K.E., TØNNESSEN F. : Determination of psilocybin in *Psilocybe semilanceata* by capillary zone electrophoresis, *Journal of Chromatographie B, Biomed Sci App.*, 1997, 694, (2), 375-81.
27. STICHT G., KÄFERSTEIN H. : Detection of psilocin in body fluids, *Forensic Science International*, 2000, 113, 403-407.
28. STRIBNY J., BOROVICKA J., SOKOL M. : Levels of psilocybin and psilocin in various types of mushrooms, *Soud Lek.*, 2003, 48, (3), 45-49.
29. SUPPRIAN T., FREY U., SUPPRIAN R., RÖSLER M., WANKE K. : Psychoactive mushrooms – an update, *Fortschritte der Neurologie Psychiatrie*, 2001, 69, (12), 597-602.

30. TSUJIKAWA K., KANAMORI T., IWATA Y., OHMAE Y., SUGITA R., INOUE H., KISHII T. : Morphological and chemical analysis of magic mushrooms in Japan, *Forensic Science International*, 2003, 138, (1-3), 85-90.

5- Psilocybine : toxicologie – « effets indésirables »

1. AMSTERDAN J. van, OPPERHUIZEN A., BRINK W. van den : Harm potential of magic mushroom use : A review, *Regulatory Toxicology and Pharmacology*, 2011, 59, 423-429.
Doi : 10.1016/j.yrtph.2011.01.006
2. ATTEMA-de JONG M.E., PORTIER C.B., FRANSSEN E.J. : Automutilation after consumption of hallucinogenic mushrooms, *Nederland Tijdschr. Geneeskde*, 2007, 151, (52), 2869-2872.
3. BARRETT F.S., BRADSTREET M.P., LEOUTSAKOS J.-M. S., JOHNSON M.W., GRIFFITHS R.R. : The Challenging Experience Questionnaire : Characterization of challenging experiences with psilocybin mushrooms, *Journal of Psychopharmacology*, 2016, 30, (12), 1279-1295.
Doi : 10.1177/0269881116678781
20. BARRETT F.S., JOHNSON M.W., GRIFFITHS R.R. : Neuroticism is associated with challenging experiences with psilocybin mushrooms, *Personnality and Individual Differences*, 2017, 117, 155-160.
Doi : 10.1016/j.paid.2017.06.004
4. BECK O., HELANDER A., KARLSON-STIBER C., STEPHANSSON N. : presence of phenylethylamine in hallucinogenic *Psilocybe* mushroom : possible role in adverse reactions, *Journal of Analytical Toxicology*, 1998, 22, (1), 45-49.
5. BOROWIAK K.S., CIECHANOWSKI K., WALOSZCZYK P. : Psilocybin Mushroom (*Psilocybe semilanceata*) Intoxication with Myocardal Infarction, *Clinical Toxicology*, 1998, 36 (1-2), 47-49.
6. CARBONARO T.M., BRADSTREET M.P., BARRETT F.S., MacLEAN K.A., JESSE R., JOHNSON M.W., GRIFFITHS R.R. : Survey study of challenging experiences after ingesting psilocybine mushrooms : Acute and enduring positive and negative consequences, *Journal of Psychopharmacology*, 2016, 1-11.
Doi : 10.1177/0269881116662634
7. DEVEAUX M., COURTECUISSE R., GOSSET D. : Aspects toxicologiques des principaux champignons hallucinogènes d'Europe, *Toxicologie Médico-Légale*, XXXVIIe Réunion Italo-Belgo-Franco-Suisse, Cluny, France, 19-20 septembre 1997, *Journal de Médecine Légale Droit Médical*, 1998, 41, (3-4), 234-239.
8. ESPIARD M.-L., LECARDEUR L., ABADIE P., HALBECQ I., DOLLFUS S. : Hallucinogen persisting perception disorder after psilocybin consumption : a case study, *European Psychiatry*, 2005, 20, 458-460.
Doi : 10.1016/j.eurpsy.2005.04.008
9. GARTZ J., FESTI F., SAMORINI G. : On the presumed French case of fatality by ingestion of Liberty Caps, *Eleusis*, 1996, 6, 40-41.
10. JOHNSON M.W., GRIFFITHS R.R., HENDRICKS P.S., HENNINGFIELD J.E. : The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act, *Neuropharmacology*, 2018, 142, 143-166.

Doi : 10.1016/j.neuropharm.2018.05.012

11. KOSENTKA P., SPRAGUE S.L., RYBERG M., GARTZ J., MAY A.L., CAMPAGNA S.R., MATHENY P.B. : Evolution of the Toxins Muscarine and Psilocybin in a Family of Mushroom-Forming Fungi, *PLOS One*, 2013, 8, (5), e64646.
Doi : 10.1371/journal.pone.0064646
12. KUNZ M.W., RAUBER-LÜTHY C., MEIER P.J., KUPFERSCHMIDT H. : Acute poisoning with hallucinogenic psilocybe mushrooms in Switzerland, *Swiss Toxicological Information Center (STIC), XX International Congress of the EAPCCT*, Amsterdam, May 2-5, 2000.
13. LASSEN J.F., RAVN H.B., LASSEN S.F. : Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms, *Ugeskr Laeger*, 1990, 152, (5), 314-317.
14. LEONARD J.B., ANDERSON B., KLEIN-SCHWARTZ W. : Does getting high hurt ? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016, *Journal of Psychopharmacology*, 2018, 32, (12), 1268-1294.
Doi : 10.1177/0269881118793086
15. LIM T.H., WASYWICH A., RUYGROK P.N. : A fatal case of « magic mushroom » ingestion in a heart transplant recipient, *Internal Medicine Journal*, 2012, 1268-1269.
16. PEDEN N.R., BISSETT A.F., MACAULAY K.E.C., CROOKS J., PELOSI A.J. : Clinical toxicology of « magic mushroom » ingestion, *Postgraduate Medical Journal*, 1981, 57, 543-545.
17. PIERROT M., JOSSE P., RASPILLER M.F., GOULMY M., RAMBOURG M.O., MANEL J., LAMBERT H. : Intoxications by hallucinogenic mushrooms, *Annales de Médecine Interne*, 2002, 153, (3 Suppl), 1S47-9.

6- Psilocybine : neurophysiologie

1. BAGGOT M.J. : Psilocybin's effects on cognition : Recent research and its implications for enhancing creativity, *Newsletter of the MAPS*, Winter 1996-1997, 7, (1), 10-11.
<http://www.maps.org/news-letters/v07n1/07110bag.html>
2. BARRETT F. S., BRADSTREET M.P., LEOUTSAKOS J.-M.S., JOHNSON M.W., GRIFFITHS R.R. : The challenging experience questionnaire : characterization of challenging experiences with psilocybin mushrooms. *Journal of Psychopharmacology*, 2016, 30, 1279-1295.
Doi : 10.1177/0269881116678781
3. BARRETT F.S., JOHNSON M.W., GRIFFITHS R.R. : Neuroticism is associated with challenging experiences with psilocybin mushrooms, *Personnalité et Individualités Différences*, 2017, 117, 155-160.
Doi : 10.1016/j.paid.2017.06.004
4. BROGAARD B., GATZIA D.E. : Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia, in « *Neuropathology of Drug Addictions and Substances Misuse, Volume 2, Chapter 83* », 2016, 890-905.

- Doi : 10.1016/B978-0-12-800212-4.00083-2
5. CATLOW B.J., SONG S., PAREDES D.A., KIRSTEIN C.L., SANCHEZ-RAMOS J. : Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditionning, *Experimental Brain Research*, 2013, 228, 481-491.
Doi : 10.1007/s00221-013-3579-0 .
 6. CARTER O.L., PETTIGREW J.D., BURR D.C., ALAIS D., HASLER F., VOLLENWEIDER F.X. : Psilocybin impairs high-level but not low-level motion perception, *NeuroReport*, 2004, 15, 12, 1947-1951.
 7. CARTER O.L., BURR D.C., PETTIGREW J.D., WALLIS G.M., HASLER F., VOLLENWEIDER F.X. : Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors, *Journal of Cognitive Neuroscience*, 2005, 17, 10, 1497-1508.
 8. CARTER O.L., PETTIGREW J.D., HASLER F., WALLIS G.M., LIU G.B., HELL D., VOLLENWEIDER F.X. : Modulating the Race and Rythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A, 5-HT1A Agonist Psilocybin, *Neuropsychopharmacology*, 2005, 30, 1154-1162.
 9. CARTER O.L., HASLER F., PETTIGREW J.D., WALLIS G.M., LIU G.B., VOLLENWEIDER F.X. : Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans, *Psychopharmacology*, 2007, 195, 415-424.
Doi : 10.1007/s00213-007-0930-9 .
 10. CARHART-HARRIS R.L., WILLIAMS T., SESSA B., TYACKEA R.J., MURPHY K., RICH A.S., FEILDING A., NUTT D.J. : The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functionnal magnetic resonance imaging environnement : a preliminary investigation of tolerability, *Journal of Psychopharmacology*, 2010.
Doi : 10.1177/0269881110367445
 11. CARHART-HARRIS R.L., ERRITZOE D., WILLIAMS T., STONE J.M., REEDA L.J., COLASANTIA A., TYACKEA R.J., LEECH R., MALIZIA A.L., MURPHY K., HOBDEN P., EVANS J., FEILDING A., WISE R.G., NUTT D.J. : Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin, *Proceedings of the National Academy of Sciences*, 2012, 109, (6), 2138-2143.
Doi : 10.1073/pnas.1119598109
 12. CARHART-HARRIS R.L., LEECH R., WILLIAMS T.M., ERRITZOE D., ABBASI N., BARGIOTAS T., HOBDEN P., SHARP D.J., EVANS J., FEILDING A., WISE R.G., NUTT D.J. : Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin, *British Journal of Psychiatry*, 2012, 200, 238-244.
Doi : 10.1192/bjp.bp.111.103309
 13. CARHART-HARRIS R.L., LEECH R., ERRITZOE D., WILLIAMS T., STONE J.M., EVANS J., SHARP D.J., FEILDING A., WISE R.G., NUTT D.J. : Functional Connectivity Measures After psilocybin Inform a Novel Hypothesis of Early Psychosis, *Schizophrenia Bulletin*, 2013, 39, (6), 1343-1351.
Doi : 10.1093/schbul/sbs117
 14. CARTER O.L., PETTIGREW J.D., BURR D.C., ALAIS D., HASLER F., VOLLENWEIDER F.X. : psilocybin impairs high-level but not low-level motion perception, *Neuroreport*, 2004, 15, (12), 1947-1951.
 15. CATLOW B.J., SONG S., PAREDES D.A., KIRSTEIN C.L., SANCHEZ-RAMOS J. : Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear

- conditionning, *Experimental Brain Research*, 2013.
- Doi : 10.1007/s00221-013-3579-0
16. Da FONSECA J.S., FIALHO M.L., GIL M.T. : Evoked Potentials and Visual Information Processing under the Action of Psilocybin in the Cat, *Neuro-Psychopharmacology*, 1965, 4, 309-3015.
 17. ESCOBAR J.A.C., ROAZZI A. : Psychological exploration of the magic mushroom (Psilocybin) experience, Part I : Subjective Effects and Time Passage Perception, *Neurobiologia*, 2011, 74, (3-4), 81-97.
 18. ESCOBAR J.A.C., ROAZZI A. : Psychological exploration of the magic mushroom (Psilocybin) experience, Part II : Neuropsychological Measures, *Neurobiologia*, 2011, 74, (3-4), 99-112.
 19. FISHER R., WARSHAY D. : Psilocybin-induced Autonomic, Perceptual, and Behavioral Change, *Neuro-Psychopharmakologie*, 1968, 1, 291-302.
 20. FISHER R., WARSHAY D. : Effects of the Psychodysleptic Drug Psilocybin on Visual Perception. Changes in Brightness Preference, *Experientia (Basel)*, 1969, 25, 166-169.
 21. GOUZOULIS-MAYFRANK E., HEEKEREN K., THELEN B., LINDENBLATT H., KOVAR K.-A., SASS H., GEYER M.A. : Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans, *Behavioural Pharmacology*, 1998, 9, 561-566.
 22. GOUZOULIS-MAYFRANK E., SCHRECKENBERGER M., SABRI O., ARNING C., THELEN B., SPITZER M., KOVAR K.-A., HERMLE L., BÜLL U., SASS H. : Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxymethylamphetamine (MDMA) and d-Methamphetamine in Healthy Volunteers. A Double-Bind, Placebo-Controlled PET Study with (18F) FDG, *Neuropsychopharmacology*, 1999, 20, (6), 565-581.
 23. GOUZOULIS-MAYFRANK E., THELEN B., MAIER S., HEEKEREN K., KOVAR K.-A., SASS H., SPITZER M. : Effects of the Hallucinogen Psilocybin on Covert Orienting of Visual Attention in Humans, *Neuropsychobiology*, 2002, 45, 205-212.
 24. GWYNNE P.H., FISCHER R., HILL R.M. : Hypnotic Induction of the Interference of Psilocybin with Optically Induced Spatial Distortion, *Pharmakopsychiatrie*, 1969, 2, (4), 223-234.
 25. HASLER F., GRIMBERG U., BENZ M.A., HUBER T., VOLLENWEIDER F.X. : Acute psychological and physiological effects of psilocybin in healthy humans : a double-bind, placebo-controlled dose-effect study, *Psychopharmacology*, 2004, 172, (2), 145-156.
Doi : 10.1007/s00213-003-1640-6
 26. HILL R.M., FISCHER R. : Induction and extinction of Psilocybin Induced Transformations of Visual Space, *Pharmakopsychiatry*, 1973, 6, 258-263.
 27. JOHNSON M.W., SEWELL R.A., GRIFFITHS R.R. : Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers, *Drug and Alcohol Dependence*, 2012, 123, (1-3), 132-140.
Doi : 10.1016/j.drugalcdep.2011.10.029
 28. KELLER M.H. : The Effects of Psilocybin on a Test of After-Image Perception, *Psychopharmacologia (Berl.)*, 1965, 8, 131-139.
 29. KOERNER J., APPEL J.B. : Psilocybin as a Discriminative Stimulus : Lack of Specificity in an Animal Behavior Model for « Hallucinogens » *Psychopharmacology*, 1982, 76, 130-135.
 30. KOMETER M., SCHMIDT A., BACHMANN R., STUDERUS E., SEIFRITZ E.,

- VOLLENWEIDER F.X. : Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State toward Positive Relative to Negative Emotions through Different Serotoninergic Subreceptors, *Biological Psychiatry*, 2012, 72, 898-906.
Doi : 10.1016/j.biopsych.2012.04.005
31. KRAEHENMANN R., PRELLER K.H., SCHEIDEgger M., POKORNY T., BOSCH O.G., SEIFRITZ E. et al. : Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers, *Biological Psychiatry*, 2014, 78, (8), 572-581.
Doi : 10.1016/j.biopsych.2014.04.010
32. KRAEHENMANN R., SCHMIDT A., FRISTON K., PRELLER K.H., SEIFRITZ E., VOLLENWEIDER F.X. : The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity, *NeuroImage : Clinical*, 2016, 11, 53-60.
Doi : 10.1016/j.nicl.2015.08.009
33. LORD L.-D., EXPERT P., ATASOY S., ROSEMAN L., RAPUANO K., LAMBIOTTE R., NUTT D.J., DECO G., CARHART-HARRIS R.L., KRINGELBACH M.L., CABRAL J. : Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin, *NeuroImage*, 2019, 199, 127-142.
Doi : 10.1016/j.neuroimage.2019.05.060
34. MARTINDALE C., FISCHER R. : The Effects of Psilocybin on Primary Process Content in Language, *Confinia Psychiatr.*, 1977, 20, 195-202.
35. MOLDAVAN M.G., GRODZINSKAYA A.A., SOLOMKO E.F., LOMBERH M.L., WASSER S.P., STOROZHUK V.M. : The effects of Psilocybe cubensis extract on hippocampal neurons in vitro, *Fiziologicheskii Zhurnal*, 2001, 47, 6, 15-23.
36. QUEDNOW B.B., KOMETER M., GEYER M.A., VOLLENWEIDER F.X. : Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers, *Neuropsychopharmacology*, 2011, 1-11.
Doi : 10.1038/npp.2011.228
37. SMIGIELSKI L., SCHEIDEgger M., KOMETER M., VOLLENWEIDER F.X. : Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects, *NeuroImage*, 2019, 196, 207-215.
Doi : 10.1016/j.neuroimage.2019.04.009
38. SPITZER M., THIMM M., HERMLE L., HOLZMANN P., KOVAR K.A., HEIMANN H., GOUZOULIS-MAYFRANK E., KISCHKA U., SCHNEIDER F. : Increased activation of indirect semantic associations under psilocybin, *Biological Psychiatry*, 1996, 39, 1055-1057.
39. STUDERUS E., GAMMA A., VOLLENWEIDER F.X. : Psychometric evaluation of the altered states of consciousness rating scale (OAV), *PLoS ONE*, 2010, 5, e12412.
Doi : 10.1371/journal.pone.0012412
40. STUDERUS E., KOMETER M., HASLER F., VOLLENWEIDER F.X. : Acute, subacute and long-term subjective effects of psilocybin in healthy humans : a pooled analysis of experimental studies, *Journal of Psychopharmacology*, 2010, 1-19.
Doi : 10.1177/0269881110382466
41. STUDERUS E., GAMMA A., KOMETER M., VOLLENWEIDER F.X. : Prediction of Psilocybin Response in Healthy Volunteers, *PLOS One*, 2012, 7, 2, e30800.
42. THATCHER K., WIEDERHOLT W.C., FISCHER R. : An Electroencephalographic Analysis of Personality-Dependent Performance under Psilocybin, *Agents and*

Actions, 1971, vol 2/1, 21-26.

43. TOSI O., ROCKEY M.A., FISCHER R. : Quantitative Measurement of Time Contraction Induced by Psilocybin, *Arzneimittel-Forsch.*, 1968, 18, 535-537.
44. TURTON S., NUTT D. J., CARHART-HARRIS R.L. : A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment, *Current Drug Abuse Reviews*, 2014, 7, (2), 117-127.
Doi : 10.2174/1874473708666150107120930
45. TYLS F., PALENICEK T., HORACEK J. : Neurobiology of the Effects of Psilocybin in Relation to its Potential Therapeutic Targets, Chapter 73, *Neuropathology of Drug Addictions and Substance Misuse, Vol 2* (Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects), 2016, 782-793.
Doi : 10.1016/B978-0-12-800212-4.00073-X
46. VARLEY T.F., CARHART-HARRIS R.L., ROSEMAN L., MENON D.K., STAMATAKIS E.A. : Serotonergic Psychedelics LSD & Psilocybin Increase the Fractal Dimension of Cortical Brain Activity in Spatial and Temporal Domains, 2019, Manuscript, 46 p.
47. VOLLENWEIDER F. X., LEENDERS K. L., SCHARFETTER C., MAGUIRE P., STADELmann O., ANGST J. : Positron emission tomography and fluorodesoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis, *Neuropsychopharmacology*, 1997, 16, 357-372.
48. VOLLENWEIDER F.X., VOLLENWEIDER -SCHERPENHUYZEN M.F., BABLER A. et al. : Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action, *Neuroreport*, 1998, 9, 17, 3897-3902.
49. WACKERMANN J., WITTMANN M., HASLER F., VOLLENWEIDER F.X. : Effects of varied doses of Psilocybin on time interval reproduction in human subjects, *Neuroscience Letters*, 2008, 435, 51-55.
Doi : 10.1016/j.neulet.2008.02.006
50. WITTMANN M., CARTER O., HASLER F., CAHN B.R., GRIMBERG U., SPRING P., HELL D., FLOHR H., VOLLENWEIDER F.X. : Effects of psilocybine on time perception and temporal control of behaviour in humans, *Journal of Psychopharmacology*, 2007, 21, (1), 50-64.
Doi : 10.1177/0269881106065859.

7- Psilocybine : expériences mystiques

1. ALLEN J.W. : Maria Sabina, saint mother of the sacred mushrooms, in Allen J.W. « *Mushrooms Pioneers* », Seattle, John Allen, 1997.
2. BARRETT F. S., JOHNSON M.W., GRIFFITHS R. R. : Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. *Journal of Psychopharmacology*, 2015, 29, 1182–1190.
Doi : 10.1177/0269881115609019
3. BECKSTEAD R.T. : Restoration and the Sacred Mushrooms : Did Joseph Smith use Psychedelic Substances to Facilitate Visionary Experiences ?, Paper presented at the Sunstone Symposium, August 2007.
4. CUMMINS C., LYKE J. : Peak Experiences of Psilocybin Users and Non-Users, *Journal of Psychoactive Drugs*, 2013, 45, (2), 189-194.
Doi : 10.1080/02791072.2013.785855
5. De FELICE P. : Poisons Sacrés, Ivresses Divines : Essai sur Quelques Formes Inferieures de la Mystique, Paris, Albin Michel, 1936.
6. FORTE R. (ed.) : Entheogens and the Future of Religion, San Francisco, Council on Spiritual Practices, 1997.
7. FURST P.T. (ed.) : Flesh of the Gods : The Ritual Use of Hallucinogens, New York, Praeger, 1972.
8. FURST P.T. : Hallucinogens and Culture, Novato, CA, Chandler & Sharp, 1976.
9. GRIFFITHS R.R., RICHARDS W.A., McCANN U., JESSE R. : Psilocybine can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance, *Psychopharmacology*, 2006, 187, 269–283.
Doi : 10.1007/s00213-006-0457-5.
10. GRIFFITHS R.R., RICHARDS W.A., JOHNSON M.W., McCANN U.D., JESSE R. : Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, *Journal of Psychopharmacology*, 2008, 22, (6), 621–632.
Doi : 10.1177/0269881108094300
11. GRIFFITHS R.R., JOHNSON M.W., RICHARDS W.A., RICHARDS B.D., McCANN U., JESSE R. : Psilocybin occasioned mystical-type experiences : immediate and persisting dose-related effects, *Psychopharmacology*, 2011, 218, (4), 649-665.
Doi : 10.1007/s00213-011-2358-5
12. GRIFFITHS R.R., JOHNSON M.W., RICHARDS W.A., RICHARDS B.D., JESSE R., MacLEAN K.A., BARRETT F.S., COSIMANO M.P., KLINEDINST M.A. : Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors, *Journal of Psychopharmacology*, 2018, 32, (1), 46-69.
Doi : 10.1177/0269881117731279
13. HARRIS L.S. (ed.) : Hallucinogens and religion : historical to scientific perspectives, Proceedings of the 63rd Annual Scientific Meeting of the College on Problems of Drug Dependence, *National Institute on Drug Abuse Research Monograph 182*, Washington DC, 2001.
14. JOHNSON M.W., HENDRICKS P.S., BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : An integrative review of epidemiology, therapeutics, mystical experience, and brain network function, *Pharmacology & Therapeutics*, 2018,

- Doi : 10.1016/j.pharmthera.2018.11.010
15. KOMETER M., SCHMIDT A., BACHMANN R., STUDERUS E., SEIFRITZ E., VOLLENWEIDER F.X. : Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors, *Biological Psychiatry*, 2012, 72, 898–906.
 Doi : 10.1016/j.biopsych.2012.04.005
16. LIGGENSTORFER R., RÄTSCH C. : Maria Sabina : Botin der Heiligen Pilze, Freiburg, Nachtschattenverlag, 1996.
51. LYKE J. : Psilocybin and Peak Experiences, Chapter 81, *Neuropathology of Drug Addictions and Substance Misuse, Vol 2* (Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects), 2016, 866-874.
 Doi : 10.1016/B978-0-12-800212-4.00081-9
17. MacLEAN K.A., JOHNSON M.W., GRIFFITHS R.R. : Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness, *Journal of Psychopharmacology*, 2011, 25, (11), 1453-1461.
 Doi : 10.1177/026988111420188
18. MacLEAN K.A., LEOUTSAKOS J.M.S., JOHNSON M.W., GRIFFITHS R.R. : Factor analysis of the mystical experience questionnaire : a study of experiences occasioned by the hallucinogen psilocybin, *Journal for the Scientific Study of Religion*, 2012, 51, 721–737.
 Doi : 10.1111/j.1468-5906.2012.01685.x
19. MASON N.L., MISCHLER E., UTHAUG M.V., KUYPERS K.P.C. : Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being, *Journal of Psychoactive Drugs*, 2019, 51, 2, 123-134.
 Doi : 10.1080/02791072.2019.1580804
20. METZNER R. : Teonanacatl : Sacred Mushroom of Visions, El Verano, CA, Four Trees, 2004.
21. METZNER R., LITWIN G., WEIL G. : The relation of expectation and mood to psilocybin reactions : a questionnaire study, *Psychedelic Review*, 1965, 5, 3–39.
22. NICHOLAS C.R., HENRIQUEZ K.M., GASSMAN M.C., COOPER K.M., MULLER D., HETZEL S., BROWN R.T., COZZI N.V., THOMAS C., HUTSON P.R. : High dose psilocybin is associated with positive subjective effects in Healthy volunteers, *Journal of Psychopharmacology*, 2018, 1-9.
 Doi : 10.1177/0269881118780713
23. RICHARDS W.A. : The psychedelic religion of mystical consciousness, *Journal of Psychedelic Studies*, 2018, 2, (1), 1-4.
 Doi : 10.1556/2054.2018.003
24. ROTHENBERG J. : Maria Sabina : Selections, Berkeley, University of California, 2003.
25. SANDFORD J. : In Search of the Magic Mushrooms, Clarkson N. Porter, New York, 1973.
26. SMIGIELSKI L., SCHEIDECKER M., KOMETER M., VOLLENWEIDER F.X. : Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects, *NeuroImage*, 2019, 196, 207-215.
 Doi : 10.1016/j.neuroimage.2019.04.009
27. UEBERSAX J.S : Selected Literature Related to Religious Use of Psilocybin Mushrooms, 2008, 1-12.

8- Psilocybine : thérapie psychédélique

1. BARNBY J.M., MEHTA M.A. : Psilocybin and Mental Health – Don't Lose Control, *Frontiers in Psychiatry*, 2018, vol 9, article 293.
Doi : 10.3389/fpsyg.2018.00293
2. BELSER A.B., AGIN-LIEBES G., SWIFT T.C., TERRANA S., DEVENOT N., FRIEDMAN H.L., GUSS J., BOSSIS A., ROSS S. : Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis, *Journal of Humanistic Psychology*, 2017.
Doi : 10.1177/0022167817706884
3. BOGENSCHUTZ M. P., POMMY J. M. : Therapeutic mechanisms of classic hallucinogens in the treatment of addictions : from indirect evidence to testable hypotheses, *Drug Testing Analysis*, 2012, 4, 543–555.
Doi : 10.1002/dta.1376
4. BOGENSCHUTZ M.P., FORCEHIMES A.A., POMMY J.A., WILCOX C.E., BARBOSA P., STRASSMAN R.J. : Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study, *Journal of Psychopharmacology*, 2015, 29, 289–299.
Doi : 10.1177/0269881114565144
5. BOGENSCHUTZ M. P., JOHNSON M. W. : Classic hallucinogens in the treatment of addictions, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2016, 64, 250–258.
Doi : 10.1016/j.pnpbp.2015.03.002
6. BOGENSCHUTZ M.P., PODREBARAC S.K., DUANE J.H., AMEGADZIE S.S., MALONE T.C., ROSS L.T., MENNENGA S.E. : Clinical Interpretations of Patients Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder, *Frontiers in Pharmacology*, 2018, 9, article 100.
Doi : 10.3389/fphar.2018.00100
7. CARBONARO T. M., BRADSTREET M. P., BARRETT F. S., MacLEAN K. A., JESSE R., JOHNSON M. W., et al. : Survey study of challenging experiences after ingesting psilocybin mushrooms : acute and enduring positive and negative consequences, *Journal of Psychopharmacology*, 2016, 30, 1268–1278.
Doi : 10.1177/0269881116662634
8. CARHART-HARRIS R.L., LEECH R., WILLIAMS T., ERRITZOE D., ABBASI N., BARGIOTAS T. et al. : Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin, *British Journal of Psychiatry*, 2012, 200, 238–244.
Doi : 10.1192/bjp.bp.111.103309
9. CARHART-HARRIS R.L., BOLSTRIDGE M., RUCKER J., DAY C.M.J., ERRITZOE D., KAELEN M., BLOOMFIELD M., RICKARD J.A., FORBES B., FEILDING A., TAYLOR D., PILLING S., CURRAN V.H., NUTT D.J. : Psilocybin with psychological support for treatment-resistant depression : an open-label feasibility study, *Lancet Psychiatry*, 2016, 3, (7), 619–627.
Doi : 10.1016/S2215-0366(16)30065-7
10. CARHART-HARRIS R.L., ROSEMAN L., BOLSTRIDGE M., DEMETRIOU L.J., PANNEKOEK N., WALL M.B., TANNER M., KAELEN M., McGONIGLE J., MURPHY K., LEECH R.H., CURRAN V., NUTT D.J. : Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms, *Scientific Reports*, 2017, volume 7, Article 13187.

11. CARHART-HARRIS R.L., BOLSTRIDGE M., DAY C.M.J., RUCKER J., WATTS R., ERRITZOE D., KAELEN M., GIRIBALDI B., BLOOMFIELD M., PILLING S., RICKARD J.A., FORBES B., FEILDING A., TAYLOR D., CURRAN H.V., NUTT D.J. : Psilocybin with psychological support for treatment-resistant depression : six-month follow-up, *Psychopharmacology*, 2018, 235, 399-408.
Doi : 10.1007/s00213-017-4771-x
12. CARHART-HARRIS R.L. : Upcoming trial - Psilocybin for major depression: A randomised control trial, Imperial College of Science, 2018,
<https://www.imperial.ac.uk/department-of-medicine/research/brainsciences/psychiatry/psychedelics/>
13. CARRILLO F., SIGMAN M., SLEZAK D. F., ASHTON P., FITZGERALD L., STROUD J., et al. : Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression, *Journal of Affective Disorders*, 2018, 230, 84-86.
Doi : 10.1016/j.jad.2018.01.006
14. CLARK B. : Some early observations on the use of psilocybin in psychiatric patients, @, 1968, 2, 21-26.
15. CROCKET R., SANDISON R.A., WALK A. : Hallucinogenic drugs and their psychotherapeutic use, Lewis, London, 1963.
16. DANIEL J., HABERMAN M. : Clinical potential of psilocybine as a treatment for mental health conditions, *Mental Health Clinician*, 2017, Vol. 7, No. 1, pp. 24-28.
Doi : 10.9740/mhc.2017.01.024
17. DELAY J., PICHOT P., LEMPERIERE T. : The Therapeutic Implications of Psilocybine, in « *Hallucinogenic drugs and their psychotherapeutic use* », Proc. Quart. Meeting Royal Medico-Psychological Association, London, Febr 1961, Edited by R. Crocket, R.A Sandison, A. Walk, Lewis, London, 1963, 37-41.
18. DELGADO P.L., MORENO F.A. : Hallucinogens, Serotonin and Obsessive-Compulsive Disorder, *Journal of Psychoactive Drugs*, 1998, 30, (4), 39-366.
19. DOBLIN R. : Dr. Leary's Concord Prison Experiment : A 34-Year Follow-Up Study, *Journal of Psychoactive Drugs*, 1998, 30, 4, 419-425.
20. DOBLIN R. : Pahnke's « Good Friday Experiment » : a Long-term Follow-up and Methodological Critique, *The Journal of Transpersonnal Psychology*, (Transpersonal Institute), 1991, 33, (1), 1-28.
21. dos SANTOS R.G., OSORIO F.L., CRIPPA J.A.S., RIBA J., ZUARDI A.W., HALLAK J.E.C. : Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years, *Therapeutic Advances in Psychopharmacology* 2016, 6, 3.
22. ERRITZOE D., ROSEMAN L., NOUR M.M., MacLEAN K., KAELEN M., NUTT D.J., CARHART-HARRIS R.L. : Effects of psilocybin therapy on personnalité structure, *Acta Psychiatrica Scandinavica*, 2018, 1-11.
Doi : 10.1111/acps.12904
23. FABRE A. : La Psilocybine : de son utilisation ancienne au cours de rituels chamaniques à sa consommation récréative actuelle en passant par son intérêt pharmaceutique, Thèse pour le Diplôme d'Etat de Docteur en Pharmacie, 16 décembre 2013, Université Claude Bernard – Lyon 1, Faculté de Pharmacie.
24. GARCIA-ROMEU A., GRIFFITHS R.R., JOHNSON M.W. : Psilocybin occasioned mystical experiences in the treatment of tobacco addiction, *Current Drug Abuse Reviews*, 2014, 7, 157-164.

Doi : 10.2174/1874473708666150107121331

25. GRIFFITHS R.R. et al. : Psychopharmacology of Psilocybin in Cancer Patients, *ClinicalTrials.gov*, NCT00465595, 2007-2016.
26. GRIFFITHS R.R., JOHNSON M.W., CARDUCCI M.A., UMBRICHT A., RICHARDS W.A., RICHARDS B.D., COSIMANO M.P., KLINEDINST M.A. : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial, *Journal of Psychopharmacology*, 2016, 30, 12, 1181– 1197.
Doi : 10.1177/0269881116675513
27. GRIFFITHS R.R., JOHNSON M.W., RICHARDS W.A., RICHARDS B.D., JESSE R., MacLEAN K.A. et al. : Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors, *Journal of Psychopharmacology*, 2017, 32, 49–69.
Doi : 10.1177/0269881117731279
28. GROB C.S. : The use of psilocybin in patients with advanced cancer and existential anxiety, in « *Psychedelic Medicine : New Evidence for hallucinogenic substances as treatments* », Vol 1, Edited by M. Winkelman abd T.B. Roberts, Praeger, Westport, Conn, 2007, pp 205-216.
29. GROB C.S., DANFORTH A.L., CHOPRA G.S., HAGERTY M., McKAY C.R., HALBERSTADT A.L., GREER G.R. : Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer, *Archives of General Psychiatry*, 2011, 68, (1), 71–78.
Doi : 10.1001/archgenpsychiatry.2010.116
30. JEROME L. : Psilocybine, Investigator's Brochure, March-April 2007.
31. JOHNSON M.W., GARCIA-ROMEU A., COSIMANO M.P., GRIFFITHS R.R. : Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction, *Journal of Psychopharmacology*, 2014, 28, (11), 983– 992.
Doi : 10.1177/0269881114548296
32. JOHNSON M.W., GARCIA-ROMEU A., GRIFFITHS R.R. : Long-term follow-up of psilocybin-facilitated smoking cessation, *American Journal of Drug Alcohol Abuse*, 2016, 43, 1, 55– 60.
Doi : 10.3109/00952990.2016.1170135
33. JOHNSON M.W., GRIFFITHS R.R. : Potential Therapeutic Effects of Psilocybin, *Neurotherapeutics*, 2017, 14, 734-740.
Doi : 10.1007/s13311-017-0542-y
34. JOHNSON M.W., GRIFFITHS R.R., HENDRICKS P.S., HENNINGFIELD J.E. : The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act, *Neuropharmacology*, 2018, 142, 143-166.
Doi : 10.1016/j.neuropharm.2018.05.012
35. KUMAR S., MITHOEFER M.C., MOJEIKO V. : Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma – Clinical Study Protocol, MAPS, 2008, 83 p.
36. LEARY T., LITWIN G., METZNER R. : Reactions to Psilocybin Administered in a Supportive Environment, *Journal of Nervous and Mental Diseases*, 1963, 137, 561-573.
Doi : 10.1097/00005053-196312000-00007

37. LEARY T., METZNER R., PRESNELL M., WEIL G., SCHWITZGEBEL R., KINNE S. : A Change Program for Adult Offenders using Psilocybin, *Psychotherapy Theory, Research and Practice*, 1965.
38. LYONS T., CARHART-HARRIS R.L. : Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression, *Journal of Psychopharmacology*, 2018, 32, 7, 811-819.
Doi : 10.1177/0269881117748902
39. LYONS T., CARHART-HARRIS R.L. : More realistic forecasting of future life events after psilocybin for treatment-resistant depression, *Frontiers in Psychology*, 2018, 9, 1721.
40. MacLEAN K., LEOUTSAKOS J-M. S., JOHNSON M.W., GRIFFITHS R.R. : Factor Analysis of the Mystical Experience Questionnaire : A Study of Experiences Occasionned by the Hallucinogen Psilocybin, *Journal for the Scientific Study of Religion*, 2012, 51, 4, 721-737.
Doi : 10.1111/j.1468-5906.2012.01685.x
41. MacALLISTER J. : Calming the Eternal Footman : Psilocybin and Cancer Psychopharmacology, *Psychedelic Press UK*, 2013.
<http://psypressuk.com/2013/02/25/calming-the-eternal-footman-p...>
42. MacCORVY J.D., OLSEN R.H., ROTH B.L. : Psilocybin for depression and anxiety associated with life-threatening illnesses, *Journal of Psychopharmacology*, 2016, 1, 2.
Doi : 10.1177/0269881116675771
43. MALONE T.C., MENNENGA S.E., GUSS J., PODREBARAC S.K., OWENS L.T., BOSSIS A.P., BELSER A.B., AGIN-LIEBES G., BOGENSCHUTZ M.P., ROSS S. : Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy, *Frontiers in Pharmacology*, 2018, 9, article 256.
Doi : 10.3389/fphar.2018.00256
44. MEIKLE S.E., LIKNAITZKY P., ROSSELL S.L., ROSS M., STRAUSS N., THOMAS N., MURRAY G., WILLIAMS M., CASTLE D.J. : Psilocybin-assisted therapy for depression : How do we advance the field ?, *Australian & New Zealand Journal of Psychiatry*, 2019, 1-7.
Doi : 10.1177/0004867419888575
45. METZNER R., LITWIN G., WEIL G.M. : The Relation of Expectation and Mood to Psilocybin Reactions : A Questionnaire Study, *The Psychedelic Review*, 1965, 3-39.
46. MITHOEFER M.C., GROB C.S., BREWERTON T.D. : Novel psychopharmacological therapies for psychiatric disorders : psilocybin and MDMA, *Lancet Psychiatry*, 2016, 3, 481-488.
Doi : 10.1016/S2215-0366(15)00576-3
47. MORENO F.A., DELGADO P., GELENBERG A.J. : Effects of Psilocybin in Obsessive-Compulsive Disorder.
<http://www.maps.org/research/psilo/azproto.html>
48. MORENO F.A., WIEGAND C.B., TAITANO E.K., DELGADO P.L. : Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder, *Journal of Clinical Psychiatry*, 2006, 67, (11), 1735-1740.
49. NUTT D. : Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future, *Journal of Psychopharmacology*, 2016, 30, 1163-4.
Doi : 10.1177/0269881116675754

50. PATRA S. : Return of the psychedelics : Psilocybin for treatment resistant depression, *Asian Journal of Psychiatry*, 2016, 24, 51-52.
Doi : 10.1016/j.ajp.2016.08.010
51. RAO I., LYDALL G. : psilocybin for the treatment of substance Use Disorders, *Advances in Psychedelic Medicine : State of the Art Therapeutic Applications*, 2019, Santa Barbara, CA, AC-CLIO, pp 127-147.
52. REICHE S., HERMLE L., GUTWINSKI S., JUNGABERLE H., GASSER P., MAJIC T. : Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2018, 81, 1-10.
Doi : 10.1016/j.pnpbp.2017.09.012
53. ROSEMAN L., NUTT D.J., CARHART-HARRIS R.L. : Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression, *Frontiers in Pharmacology*, 2018, 8, article 974.
Doi : 10.3389/fphar.2017.00974
54. ROSEMAN L., DEMETRIOU L., WAL M.B., NUTT D.J., CARHART-HARRIS R.L. : Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression, *Neuropharmacology*, 2018, 142, 263e269.
Doi : 10.1016/j.neuropharm.2017.12.041
55. ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. : Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial, *Journal of Psychopharmacology*, 2016, 30, 12, 1165– 1180.
Doi : 10.1177/0269881116675512 ClinicalTrials.gov : NCT00957359
56. SCHARFETTER A. : Athena Awakening : A Theoretical Exploration of Cathartic Integration within Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, San Fancisco, CA, 2017.
57. SEWELL R.A., HALPERN J.H., POPE H.G. : Response of cluster headache to psilocybin and LSD, *Neurology*, 2006, 66, 1920-1922.
58. TAP S. : Mechanisms of Therapeutic Action of Psilocybin Cubensis in Treating Patients with Depression, 2018
https://www.researchgate.net/publication/328942733_Mechanisms_of_Therapeutic_Action_of_Psilocybin_Cubensis_in_Treating_Patients_with_Depression
59. THOMAS K., MALCOLM B., LASTRA D. : Psilocybin-assisted therapy : A review of a novel treatment for psychiatric disorders, *Journal of Psychoactive Drugs*, 2017, 49, (5), 446–455.
Doi : 10.1080/02791072.2017.1320734
60. VARLEY J. : Psychedelic-assisted therapy for anxiety and depression in the face of death : A critical review with an anthropological lens, *Journal of Psychedelic Studies*, 2019, 3, (1), 14–18.
Doi : 10.1556/2054.2019.005
61. WATTS R., KRZANOWSKI, J., DAY C., CARHART-HARRIS R. : Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant Depression, *Journal of Humanistic Psychology*, 2017, 57, 5, 002216781770958
<https://www.youtube.com/watch?v=CFoT2CMomL4>